Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases

Recruitment & Eligibility

Inclusion Criteria

Nasopharyngeal carcinoma liver metastases (NCLM) are diagnosed by pathological confirmation of liver biopsy or imaging findings combined with clinical history.
ECOG score ≤ 2 points.
1. Patients with no recurrence of the primary tumor and oligometastasis in the liver. 2. Patients with multiple metastases (bone) without primary tumor recurrence and liver metastases have stable disease (SD) or partial remission (PR) or complete remission (CR) after systemic treatment except for liver lesions. 3. Patients with primary tumor recurrence and liver metastasis (may be combined with bone metastasis) have SD or PR or CR after systemic treatment except for liver lesions.
Able to perform radical resection of liver lesions.
Good liver function (Child-Pugh grade A liver function, estimated remaining liver volume ≥ 30%).
Blood test, coagulation function, liver and kidney function, electrocardiogram, chest X-ray and other preoperative examinations show no clear contraindications for surgery.
Expected survival ≥ 6 months.
Those who voluntarily participate in this study and signe the informed consent form.

Exclusion Criteria

Younger than 18 or older than 70 years old.
ECOG score > 2 points.
Combined with distant metastasis other than liver and bone.
Disease progression (PD) after systemic treatment of the primary tumor and bone metastases.
The liver lesion cannot be resected by R0.
Insufficient liver reserve function (preoperative liver function Child-Pugh B or C grade and cannot be reduced to A grade in a short time, or estimated remaining liver volume <30%).
Combined with surgical contraindications in the preoperative examination, such as cardiac clinical symptoms or diseases that are not well controlled, abnormal coagulation function with bleeding tendency, or receiving thrombolytic therapy, etc..
Liver metastases have received local treatment for liver metastases such as interventional and radiofrequency.
Pregnant or lactating women.
History of malignant tumors in other parts, severe mental illness, etc..
Patients or family members cannot understand the conditions and objectives of this study.

Study & Design

Arm && Interventions

Group	Intervention	Description
Hepatectomy group	Hepatectomy	Patients in the hepatectomy group receive hepatectomy, which could be combined with radiotherapy and chemotherapy for the primary tumor during the perioperative period.

Primary Outcome Measures

Name	Time	Method
Overall survival time	up to 60 months	Refers to the time from liver resection to death from any cause.

Secondary Outcome Measures

Name	Time	Method
Perioperative morbidity rate	3 months	Refers to the incidence of perioperative complications.
Perioperative mortality rate	1 month	Refers to the mortality rate of patients within 30 days after liver resection.
Unplanned reoperation rate	1 month	Refers to the unplanned reoperation rate due to various reasons during the same hospitalization.
Intrahepatic recurrence-free survival	up to 60 months	Refers to the time from the start of liver resection to the date of confirmation of intrahepatic tumor recurrence or death from any cause, whichever is earlier, in patients who underwent hepatectomy.

Recruitment & Eligibility